The tau stage I–V composite region (cut‐off > 1.41 SUVR) had 0% sensitivity for preclinical AD, 64% sensitivity for prodromal AD and 92% sensitivity for AD dementia. This evidence concerns the gene MAPT and Alzheimer disease.